0 377

Cited 2 times in

Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer

DC Field Value Language
dc.contributor.author금웅섭-
dc.contributor.author김용배-
dc.contributor.author장지석-
dc.contributor.author김용배-
dc.contributor.author장지석-
dc.date.accessioned2019-02-14T01:53:51Z-
dc.date.available2019-02-14T01:53:51Z-
dc.date.issued2018-
dc.identifier.issn0090-8258-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/167281-
dc.description.abstractOBJECTIVE: The feasibility of salvage radiotherapy (RT) for patients with recurrent cervical cancer after definitive treatment is contentious. The purpose of this study was to investigate the feasibility and benefit of RT, particularly intensity-modulated RT (IMRT), for salvage treatment in patients with recurrent cervical cancer. METHODS: We retrospectively analyzed 125 patients with recurrent cervical cancer treated with RT at Yonsei Cancer Center between January 2007 and December 2016. All patients received salvage RT for the recurred or metastatic tumor mass. Irradiating dose and volume were determined depending on initial treatment. IMRT was selected in challenging cases, such as re-irradiation or for patients for whom implementing a satisfactory 3-dimensional conformal RT plan was challenging. RESULTS: The median follow-up period was 5.5 years (range, 10.8 months to 41 years). The 5-year local failure-free survival (LFFS) and progression-free survival (PFS) rates were 63.9% and 39.6%, respectively. The 5-year overall survival (OS) rate was 66%; 10-year OS reached 51%. The median PFS rates in patients with locoregional failure, distant metastases, or both were 45.4, 29.1, and 14.7 months, respectively (p = 0.005). For the 45 patients that received re-irradiation, 5-year LFFS, PFS, and OS rates were 47.1%, 33.2%, and 66.5%, respectively. Late complications were observed in 12 patients (12/125, 9.6%). CONCLUSIONS: Our data suggest that salvage RT is safe and effective against recurrent cervical cancer. IMRT is a safe and effective salvage modality for these patients, including those requiring re-irradiation.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherAcademic Press-
dc.relation.isPartOfGYNECOLOGIC ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Recurrence, Local/mortality-
dc.subject.MESHNeoplasm Recurrence, Local/pathology-
dc.subject.MESHNeoplasm Recurrence, Local/radiotherapy*-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHRadiotherapy, Intensity-Modulated*/adverse effects-
dc.subject.MESHSalvage Therapy-
dc.subject.MESHUterine Cervical Neoplasms/mortality-
dc.subject.MESHUterine Cervical Neoplasms/pathology-
dc.subject.MESHUterine Cervical Neoplasms/radiotherapy*-
dc.titleRadiotherapy is a safe and effective salvage treatment for recurrent cervical cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorHyun Ju Kim-
dc.contributor.googleauthorJee Suk Chang-
dc.contributor.googleauthorWoong Sub Koom-
dc.contributor.googleauthorKyu Chan Lee-
dc.contributor.googleauthorGwi Eon Kim-
dc.contributor.googleauthorYong Bae Kim-
dc.identifier.doi10.1016/j.ygyno.2018.08.029-
dc.contributor.localIdA00273-
dc.contributor.localIdA00744-
dc.contributor.localIdA00744-
dc.contributor.localIdA04658-
dc.contributor.localIdA04658-
dc.contributor.localIdA00744-
dc.contributor.localIdA00744-
dc.contributor.localIdA04658-
dc.contributor.localIdA04658-
dc.relation.journalcodeJ00956-
dc.identifier.eissn1095-6859-
dc.identifier.pmid30195468-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0090825818311582-
dc.subject.keywordCervical cancer-
dc.subject.keywordIntensity-modulated-
dc.subject.keywordRadiotherapy-
dc.subject.keywordRecurrence-
dc.subject.keywordSalvage therapy-
dc.contributor.alternativeNameKoom, Woong Sub-
dc.contributor.affiliatedAuthor금웅섭-
dc.contributor.affiliatedAuthor김용배-
dc.contributor.affiliatedAuthor김용배-
dc.contributor.affiliatedAuthor장지석-
dc.contributor.affiliatedAuthor장지석-
dc.contributor.affiliatedAuthor김용배-
dc.contributor.affiliatedAuthor김용배-
dc.contributor.affiliatedAuthor장지석-
dc.contributor.affiliatedAuthor장지석-
dc.citation.volume151-
dc.citation.number2-
dc.citation.startPage208-
dc.citation.endPage214-
dc.identifier.bibliographicCitationGYNECOLOGIC ONCOLOGY, Vol.151(2) : 208-214, 2018-
dc.identifier.rimsid61485-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.